Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Efficacy and Safety of Risperidone in Long-acting Microspheres in Patients With Schizophrenia, Schizophreniform or Schizoaffective Disorders Diagnosed According to the DSM-IV Criteria, After Switching Treatment With Any Antipsychotic Therapy With Long-acting Microspheres of Risperidone

NCT01855074 is registered in ClinicalTrials.gov with Janssen-Cilag Ltd. as lead sponsor.

NCT NCT01855074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01855074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Efficacy and Safety of Risperidone in Long-acting Microspheres in Patients With Schizophrenia, Schizophreniform or Schizoaffective Disorders Diagnosed According to the DSM-IV Criteria, After Switching Treatment With Any Antipsychotic Therapy With Long-acting Microspheres of Risperidone
Lead sponsor
Janssen-Cilag Ltd.
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2007
Completion date
February 28, 2009
Enrollment
80 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia, schizophreniform disorder